About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is a company based in Cambridge (United States) founded in 2013 by Joshua Cohen and Justin Klee.. Amylyx Pharmaceuticals has raised $171.83 million across 7 funding rounds from investors including Bain Capital, Marshall Wace and Perceptive Advisors. The company has 123 employees as of December 31, 2024. Amylyx Pharmaceuticals offers products and services including Therapy Pipeline and Clinical Trials. Amylyx Pharmaceuticals operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter Cambridge, United States
- Employees 123 as on 31 Dec, 2024
- Founders Joshua Cohen, Justin Klee
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Amylyx Pharmaceuticals, Inc.
-
Annual Revenue
$87.37 M-77.06as on Dec 31, 2024
-
Net Profit
$-301.74 M-712.42as on Dec 31, 2024
-
EBITDA
$-254.77 M-738.69as on Dec 31, 2024
-
Total Equity Funding
$171.83 M (USD)
in 7 rounds
-
Latest Funding Round
$135 M (USD), Series C
Jul 20, 2021
-
Investors
Bain Capital
& 15 more
-
Employee Count
123
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol AMLX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Amylyx Pharmaceuticals
Amylyx Pharmaceuticals offers a comprehensive portfolio of products and services, including Therapy Pipeline and Clinical Trials. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops treatments for neurological and metabolic disorders via trials
Conducts studies for diseases like ALS and PBH
Unlock access to complete
Unlock access to complete
Leadership Team
11 people
Finance and Accounting
5 people
Legal and Compliance
4 people
Head Team
3 people
Software Development Team
3 people
Data Analysis and Operations Team
2 people
Sales and Marketing
2 people
Human Resources and Administration
2 people
Unlock access to complete
Funding Insights of Amylyx Pharmaceuticals
Amylyx Pharmaceuticals has successfully raised a total of $171.83M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $135 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series C — $135.0M
-
First Round
First Round
(17 Nov 2015)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Series C - Amylyx Pharmaceuticals | Valuation | Viking Global Investors | |
| Jul, 2020 | Amount | Series B - Amylyx Pharmaceuticals | Valuation | Morningside |
|
| Nov, 2018 | Amount | Debt – Conventional - Amylyx Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Amylyx Pharmaceuticals
Amylyx Pharmaceuticals has secured backing from 16 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Bain Capital, Marshall Wace and Perceptive Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Debt and equity investments are pursued across multiple sectors.
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Amylyx Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Amylyx Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Amylyx Pharmaceuticals Comparisons
Competitors of Amylyx Pharmaceuticals
Amylyx Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| domain | founded_year | HQ Location |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| domain | founded_year | HQ Location |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Amylyx Pharmaceuticals
Frequently Asked Questions about Amylyx Pharmaceuticals
When was Amylyx Pharmaceuticals founded?
Amylyx Pharmaceuticals was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Where is Amylyx Pharmaceuticals located?
Amylyx Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Amylyx Pharmaceuticals?
Joshua Cohen is the current CEO of Amylyx Pharmaceuticals. They have also founded this company.
Is Amylyx Pharmaceuticals a funded company?
Amylyx Pharmaceuticals is a funded company, having raised a total of $171.83M across 7 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $12.98M, raised on Nov 17, 2015.
How many employees does Amylyx Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Amylyx Pharmaceuticals is 123.
What is the annual revenue of Amylyx Pharmaceuticals?
Annual revenue of Amylyx Pharmaceuticals is $87.37M as on Dec 31, 2024.
What does Amylyx Pharmaceuticals do?
Amylyx Pharmaceuticals was founded in 2013 in Cambridge, United States, within the biotechnology sector. Small-molecule therapeutics are developed by the company for neurodegenerative diseases, including amyotrophic lateral sclerosis and Alzheimers disease. A combination therapy is offered that addresses mitochondrial stress and endoplasmic reticulum stress through two synergistic components. Operations focus on formulation and clinical advancement of these treatments.
Who are the top competitors of Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals's top competitors include Alector, Entrada Therapeutics and Annexon.
What products or services does Amylyx Pharmaceuticals offer?
Amylyx Pharmaceuticals offers Therapy Pipeline and Clinical Trials.
Is Amylyx Pharmaceuticals publicly traded?
Yes, Amylyx Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol AMLX.
Who are Amylyx Pharmaceuticals's investors?
Amylyx Pharmaceuticals has 16 investors. Key investors include Bain Capital, Marshall Wace, Perceptive Advisors, Verition Fund Management, and Viking Global Investors.
What is Amylyx Pharmaceuticals's ticker symbol?
The ticker symbol of Amylyx Pharmaceuticals is AMLX on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.